Table of Contents
ISRN Urology
Volume 2013 (2013), Article ID 458353, 7 pages
http://dx.doi.org/10.1155/2013/458353
Review Article

Should Finasteride Be Routinely Given Preoperatively for TURP?

1Department of Urology, University Hospital of Wales, Cardiff CF14 4XW, UK
2Royal Bournemouth Hospital, Bournemouth, UK

Received 28 April 2013; Accepted 19 June 2013

Academic Editors: A. K. Singla and H. Tezval

Copyright © 2013 O. M. Aboumarzouk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Donohue, D. Hayne, U. Karnik, D. R. Thomas, and M. C. Foster, “Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks,” BJU International, vol. 96, no. 9, pp. 1319–1322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Häggström, N. Tørring, K. Møller et al., “Effects of finasteride on vascular endothelial growth factor—a placebo-controlled randomized study in BPH patients,” Scandinavian Journal of Urology and Nephrology, vol. 36, no. 3, pp. 182–187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Puchner and M. I. Miller, “The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report,” Journal of Urology, vol. 154, no. 5, pp. 1779–1782, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. McConnell, J. D. Wilson, F. W. George, J. Geller, F. Pappas, and E. Stoner, “Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia,” Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 3, pp. 505–508, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Pareek, M. Shevchuk, N. A. Armenakas et al., “The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients,” Journal of Urology, vol. 169, no. 1, pp. 20–23, 2003. View at Google Scholar · View at Scopus
  6. M. T. Sutton, M. Yingling, A. Vyas et al., “Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells,” Prostate, vol. 66, no. 11, pp. 1194–1202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Donohue, H. Sharma, R. Abraham, S. Natalwala, D. R. Thomas, and M. C. Foster, “Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss,” Journal of Urology, vol. 168, no. 5, pp. 2024–2026, 2002. View at Google Scholar · View at Scopus
  8. J. A. Hagerty, P. C. Ginsberg, J. D. Harmon, and R. C. Harkaway, “Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate,” Urology, vol. 55, no. 5, pp. 684–689, 2000. View at Google Scholar · View at Scopus
  9. W. K. Mebust, H. L. Holtgrewe, A. T. K. Cockett, and P. C. Peters, “Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients,” Journal of Urology, vol. 141, no. 2, pp. 243–247, 1989. View at Google Scholar · View at Scopus
  10. Ö. L. Özdal, C. Özden, K. Benli, S. Gökkaya, S. Bulut, and A. Memiş, “Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study,” Prostate Cancer and Prostatic Diseases, vol. 8, no. 3, pp. 215–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Sandfeldt, D. M. Bailey, and R. G. Hahn, “Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride,” Urology, vol. 58, no. 6, pp. 972–976, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. Donohue and N. J. Barber, “How do we investigate haematuria and what role has finasteride?” BJU International, vol. 93, no. 1, pp. 3–4, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. K. T. McVary, C. G. Roehrborn, A. L. Avins et al., “Update on AUA guideline on the management of benign prostatic hyperplasia,” Journal of Urology, vol. 185, no. 5, pp. 1793–1803, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. G. S. Higgins, “Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration,” 2011, http://www.cochrane-handbook.org/.
  15. L. E. Kavanagh, G. S. Jack, and N. Lawrentschuk, “Prevention and management of TURP-related hemorrhage,” Nature Reviews Urology, vol. 8, no. 9, pp. 504–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. J. Foley, L. Z. Soloman, A. W. Wedderburn et al., “A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride,” Journal of Urology, vol. 163, no. 2, pp. 496–498, 2000. View at Google Scholar · View at Scopus
  17. J. A. Arratia-Maqueo, R. Garza-Cortés, L. S. Gómez-Guerra, and J. R. Cortés-Gonzlez, “Effect of one month treatment with dutasteride on transurethral resection of the prostate,” Actas Urologicas Espanolas, vol. 34, no. 10, pp. 866–869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. G. Hahn, T. Fagerström, T. L. J. Tammela et al., “Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride,” BJU International, vol. 99, no. 3, pp. 587–594, 2007. View at Publisher · View at Google Scholar · View at Scopus